Pulse Check: The Cardiovascular Conversations | Ep 1: Coronary Inflammation—The Next Frontier in Cardiovascular Risk Management

Host: Dr. Cheerag Shirodaria, VP and Cardiovascular/Metabolic Therapeutic Area Head, FortreaParticipant: Chris Farina, Abcentra CEO Description: Despite advances in lipid-lowering and antithrombotic therapies, residual cardiovascular risk remains a major challenge. In this episode, Dr. Cheerag Shirodaria, Fortrea's cardiovascular lead, and Chris Farina, CEO of Abcentra, explore the emerging science behind coronary inflammation as a key driver of atherosclerotic disease. They discuss why inflammation, particularly in vulnerable coronary plaques, is gaining traction as a therapeutic target, and talk about Abcentra’s first-in-class monoclonal antibody - designed to selectively quell inflammation in diseased arterial tissue. With insights from landmark trials, and a look at how these new options differs from systemic anti-inflammatory agents, this episode offers a compelling case for a paradigm shift in cardiovascular drug development. If you're working in CV research, this is a must-listen.